Mansour Poorebrahim

1.6k total citations
49 papers, 955 citations indexed

About

Mansour Poorebrahim is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mansour Poorebrahim has authored 49 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Mansour Poorebrahim's work include CAR-T cell therapy research (14 papers), Multiple Myeloma Research and Treatments (9 papers) and Peptidase Inhibition and Analysis (6 papers). Mansour Poorebrahim is often cited by papers focused on CAR-T cell therapy research (14 papers), Multiple Myeloma Research and Treatments (9 papers) and Peptidase Inhibition and Analysis (6 papers). Mansour Poorebrahim collaborates with scholars based in Iran, Germany and Canada. Mansour Poorebrahim's co-authors include Ángel Cid-Arregui, Mikael Björnstedt, Dhifaf Sarhan, Ali Razaghi, Hassan Askari, Hamed Haghi‐Aminjan, Mohammad Abdollahı, Stina L. Wickström, Rolf Kiessling and Elham Fakhr and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Mansour Poorebrahim

47 papers receiving 945 citations

Peers

Countries citing papers authored by Mansour Poorebrahim

Since Specialization

Citations

This map shows the geographic impact of Mansour Poorebrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mansour Poorebrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mansour Poorebrahim more than expected).

Fields of papers citing papers by Mansour Poorebrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mansour Poorebrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mansour Poorebrahim. The network helps show where Mansour Poorebrahim may publish in the future.

Co-authorship network of co-authors of Mansour Poorebrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Mansour Poorebrahim. A scholar is included among the top collaborators of Mansour Poorebrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mansour Poorebrahim. Mansour Poorebrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma 2024 ·Blood ·Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, (unknown), Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, (unknown), Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis	16
2	Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma 2024 ·Blood ·Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, (unknown), Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence Boise, Paola Neri, Nizar J. Bahlis	1
3	Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma 2024 ·Blood ·Noémie Leblay, Sungwoo Ahn, Holly Lee, Matteo Da Vià, Mansour Poorebrahim, Sacha Benaoudia, (unknown), (unknown), Niccolò Bolli, Nizar J. Bahlis, Paola Neri	0
4	A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7 2023 ·Cancer Letters ·Mansour Poorebrahim, (unknown), Frederik Marmé, Stefan Burdach, Ángel Cid-Arregui	15
5	Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency 2023 ·Blood ·Noémie Leblay, Sungwoo Ahn, (unknown), Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence Boise, Nizar J. Bahlis, Paola Neri	14
6	Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells 2023 ·Blood ·Mansour Poorebrahim, Holly Lee, Sacha Benaoudia, Ranjan Maity, Sungwoo Ahn, Noémie Leblay, Elie Barakat, (unknown), Douglas J. Mahoney, Lawrence Boise, Paola Neri, Nizar J. Bahlis	2
7	Update on immune‐based therapy strategies targeting cancer stem cells 2023 ·Cancer Medicine ·(unknown), Niloufar Mohammadkhani, (unknown), (unknown), (unknown), (unknown), Mansour Poorebrahim, Marzieh Ebrahimi	14
8	T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer 2022 ·Cancers ·(unknown), (unknown), (unknown), Mansour Poorebrahim, Melanie Thiede, Kilian Schober, Josef Mautner, Julia Hauer, Jürgen Ruland, Dirk H. Busch, Uwe Thiel, Stefan Burdach	1
9	Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors 2022 ·PLoS Computational Biology ·Mansour Poorebrahim, Mohammad Foad Abazari, (unknown), Behzad Shahbazi, Reza Mahmoudi, (unknown), Hassan Askari, Ladan Teimoori‐Toolabi	5
10	Selenium stimulates the antitumour immunity: Insights to future research 2021 ·European Journal of Cancer ·Ali Razaghi, Mansour Poorebrahim, Dhifaf Sarhan, Mikael Björnstedt	150
11	Recombinant immunotoxins development for HER2-based targeted cancer therapies 2021 ·Cancer Cell International ·Reza Mahmoudi, Hassan Dianat‐Moghadam, Mansour Poorebrahim, (unknown), Vahdat Poortahmasebi, (unknown), Mohammad Rahmati	25
12	Correction: TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential 2021 ·Cancer Gene Therapy ·Mansour Poorebrahim, Niloufar Mohammadkhani, Reza Mahmoudi, (unknown), Elham Fakhr, Ángel Cid-Arregui	1
13	TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential 2021 ·Cancer Gene Therapy ·Mansour Poorebrahim, Niloufar Mohammadkhani, Reza Mahmoudi, (unknown), Elham Fakhr, Ángel Cid-Arregui	40
14	A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review 2018 ·Pharmacological Research ·Hassan Askari, (unknown), Mansour Poorebrahim, Hamed Haghi‐Aminjan, (unknown), Mohammad Abdollahı	147
15	Structural and dynamic characterization of human Wnt2-Fzd7 complex using computational approaches 2018 ·Journal of Molecular Modeling ·(unknown), Mansour Poorebrahim, Hamzeh Rahimi, Ali Akbar Shabani, Morteza Karimipoor, Mohammad Reza Akbari Eidgahi, Ladan Teimoori‐Toolabi	10
16	Nanosized aptameric cavities imprinted on the surface of magnetic nanoparticles for high-throughput protein recognition 2018 ·Microchimica Acta ·(unknown), Seyede Zohreh Mirahmadi‐Zare, (unknown), (unknown), Mansour Poorebrahim, Mohammad Hossein Nasr‐Esfahani	35
17	Can any “non-specific charge modification within microtubule binding domains of Tau” be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform 2017 ·International Journal of Biological Macromolecules ·(unknown), Mohammad Reza Ashrafi-Kooshk, Seyed Shahriar Arab, Saeed Karima, Mansour Poorebrahim, Seyyed Abolghasem Ghadami, Ali Akbar Moosavi‐Movahedi, Reza Khodarahmi‬	10
18	Rational design of DKK3 structure-based small peptides as antagonists of Wnt signaling pathway and in silico evaluation of their efficiency 2017 ·PLoS ONE ·Mansour Poorebrahim, Solmaz Sadeghi, Hamzeh Rahimi, Morteza Karimipoor, Kayhan Azadmanesh, Mohammad Ali Mazlomi, Ladan Teimoori‐Toolabi	18
19	HBsAg mutations related to occult hepatitis B virus infection in HIV‐positive patients result in a reduced secretion and conformational changes of HBsAg 2016 ·Journal of Medical Virology ·(unknown), (unknown), Frank Tacke, Eray Yagmur, Vahdat Poortahmasebi, Mansour Poorebrahim, Minoo Mohraz, (unknown), Mehrnaz Rasoolinejad, (unknown), (unknown), Zahra Fakhari, Mehdi Norouzi, (unknown), (unknown), Seyed Moayed Alavian, Seyed Mohammad Jazayeri	21
20	HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer 2016 ·Recent Patents on Anti-Cancer Drug Discovery ·Maryam Iman, (unknown), Seyed Shahriar Arab, (unknown), Mansour Poorebrahim	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact